Executive Management
Dr. Vladimir Cmiljanovic
Chief Executive Officer
Dr. Vladimir Cmiljanovic is a renowned serial biotech entrepreneur, cancer scientist, and medicinal chemist with over 15 years of experience in oncology drug development.
Andreas Emmenegger
Chief Financial Officer / Chief Business Officer
Andreas has more than 20 years of experience as the CFO of public and private multinational companies, including 15 years in the biotech industry.
Dr. Nadezda Gracheva
Chief Operating Officer
Dr. Nadezda Gracheva is a scientist with a background in Radiochemistry and Radiopharmacy as a branch of Nuclear Medicine. She obtained a Ph.D. degree at ETH Zurich, where she was responsible for the development of novel radioactive nuclides for Targeted Radionuclide Therapy to promote innovative cancer treatments.
Prof. Dr. Andreas Türler
Chief Radiochemist
Prof. Dr. Andreas Türler is the Chief Radiochemist at Torpedo and publisher of 157 peer reviewed articles. Andreas has been a full professor at the University of Bern and head of the Laboratory of Radiochemistry at the Paul Scherrer Institute (LRC) for 15 years.
Dr. Bruno Osterwalder
Chief Medical Officer
Dr. Bruno Osterwalder is an esteemed figure in the realm of hematology and oncology, with a wealth of experience spanning 15 years in academic clinical practice. With Swiss board certifications, his journey has been a testament to his expertise in internal medicine, hematology, and oncology.
Dr. Doriano Fabbro
Chief Scientific Officer
Dr. Doriano Fabbro is a renowned drug discovery and kinase expert with more than 20 years’ experience in the pharmaceutical industry, following 10 years in academia. Until 2005, Doriano was an Executive Director for the Oncology Drug Discovery Division of the Novartis Institute for Biomedical Research (NIBR) in Basel, Switzerland and was a member of the NIBR Oncology Advisory Board overseeing the oncology portfolio from target discovery to clinical development.
Dr. Milan Crnogorac
Chief Technology Officer
Dr. Milan Crnogorac is an experienced executive responsible for providing strategic, financial and operational leadership for the Technical Operations, Project Management and CapEx spending.
Dr. Paul Hebeisen
Head of Medicinal Chemistry
Dr. Paul Hebeisen is a highly experienced medicinal chemist with an impressive track record in drug discovery over 28 years of service at F. Hoffmann-La Roche AG, Switzerland. Paul served in various positions, most notably as a Group Leader in Chemistry in the discovery of novel anti-infectives.
Dr. Aurélie Jenn
Head of Regulatory Affairs & Quality Assurance
Dr. Aurélie Jenn, Head of Regulatory Affairs and Quality Assurance, is a pharmacist (Pharm. D) bringing over 20 years of experience in the pharmaceutical industry. In a first part of her career, she worked in Regulatory Affairs / CMC writing for generic products and New Chemical Entities in Switzerland and France, having close interactions and providing support to technical departments.
David Allman
Head of Clinical Operations
David Allman is a biochemist by training and has over 25 years of global experience in the pharmaceutical industry having worked for pharmaceutical companies and leading clinical research organizations as well as applying his expertise in the virtual development arena.
Dr. Emilie Frugier
Head of Intellectual Property
Dr. Frugier is an experienced patent manager and a qualified European Patent Attorney with a focus on supporting small to mid-sized biotech entities in protecting and securing access to intellectual property assets critical to their competitiveness and fundraising.
Dr. Dirk Mossmann
Scientific Project Manager
Dr. Dirk Mossmann is a cancer biologist with broad expertise in mTOR signaling and cancer metabolism. He studied molecular medicine in Freiburg (Germany) and obtained his Ph.D. in the department of biochemistry.
Helene Muller
Clinical Operations Manager
Helene Muller has over 25 years of experience in the pharmaceutical industry managing numerous clinical projects for leading clinical research organizations but also working as a consultant supporting mainly small and mid-sized biotechnology companies in project oversight and implementation.
Debora Foglia
Chief Legal Officer
Debora Foglia joined the company as Legal Counsel of Swiss Rockets AG and its subsidiary companies in January 2023. She is an attorney-at-law and holds a bachelor’s and master’s degree in law of the University of Basel.